Clinical proteomics: Towards early detection of cancers;Protéomique clinique: Vers la détection précoce des cancers?

Medecine/Sciences

Volumn 21, Issue 8-9, 2005, Pages 722-728

  Solassol, Jérôme ^a   Boulle, Nathalie ^a   Maudelonde, Thierry ^a   Mangé, Alain ^a  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CYTOKERATIN 19 FRAGMENT; NEURON SPECIFIC ENOLASE; PROSTATE SPECIFIC ANTIGEN; THYROGLOBULIN; TUMOR MARKER;

AFFINITY CHROMATOGRAPHY; CALCULATION; CANCER; CANCER DIAGNOSIS; CANCER GROWTH; CANCER SURVIVAL; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HUMAN; INSTRUMENTATION; PROTEOMICS; REVIEW; STANDARDIZATION; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; SURVIVAL TIME; VALIDATION PROCESS;

EID: 30344482279     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/2005218-9722     Document Type: Review

References (56)

1. Lescuyer P, Chevallet M, Rabilloud T. Concepts and therapeutic perspectives of proteomics. Med Sci (Paris) 2004; 20: 587-92.
2. Lim MS, Elenitoba-Johnson KS. Proteomics in pathology research. Lab Invest 2004; 84: 1227-44.
3. Chong BE, Lubman DM, Rosenspire A, Miller F. Protein profiles and identification of high performance licuid chromatography isolated proteins of cancer cell lines using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 1998 12: 1986-93.
4. O'Neil KA, Miller FR, Barder TJ, Lubman DM. Profiling the progression of cancer: separation of microsomal proteins in MCF10 breast epithelial cell lines using nonporous chromatophoresis. Proteomics 2003; 3: 1256-69.
5. Zhu K, Kim J, Yoo C, et al. High sequence coverage of proteins isolated from liquid separations of breast cancer cells using capillary electrophoresis-time-of-flight MS and MALDI-TOF MS mapping. Anal Chem 2003; 75: 6209-17.
6. Issaq HJ, Veenstra TD, Conrads TP, Felschow D. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 2002; 292: 587-92.
7. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359: 572-7.
8. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 2004; 3: 367-78.
9. Zhang Z, Bast RC, Jr., Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004; 64: 5882-90.
10. Diamandis EP. Proteomic patterns in serum and identification of ovarian cancer. Lancet 2002; 360: 170; author reply 170-1.
11. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 2004; 96: 353-6.
12. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-7.
13. Mehta AI, Ross S, Lowenthal MS, et al. Biomarker amplification by serum carrier protein binding. Dis Markers 2003; 19: 1-10.
14. Liotta LA, Ferrari M, Petricoin E. Clinical proteomics: written in blood. Nature 2003; 425: 905.
15. Mok SC, Chao J, Skates S, et al. Prostosin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst 2001; 93: 1458-64.
16. Matrisian LM, Sledge GW, Jr., Mohla S. Extracellular proteolysis and cancer: meeting summary and future directions. Cancer Res 2003; 63: 6105-9.
17. Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocrinol Rev 2001; 22: 184-204.
18. Petricoin E, 3rd, Liotta LA. Counterpoint: the vision for a new diagnostic paradigm. Clin Chem 2003; 49: 1276-8.
19. Diamandis EP. Point: proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem 2003; 49: 1272-5.
20. Solassol J, Marin P, Demettre E, et al. Proteomic detection of prostate-specific antigen using a serum fractionation procedure: potential implication for new low-abundance cancer biomarkers detection. Anal Biochem 2005; 338: 26-31.
21. Merrell K, Southwick K, Graves SW, et al. Analysis of low-abundance, low-molecular-weight serum proteins using mass spectrometry. J Biomol Tech 2004; 15: 238-48.
22. Wang YY, Cheng P, Chan DW. A simple affinity spin tube filter method for removing high-abundant common proteins or enriching low-abundant biomarkers for serum proteomic analysis. Proteomics 2003; 3: 243-8.
23. Govorukhina NI, Keizer-Gunnink A, Van der Zee AG, et al. Sample preparation of human serum for the analysis of tumor markers. Comparison of different approaches for albumin and gamma-globulin depletion. J Chromatogr A 2003; 1009: 171-8.
24. Petricoin EF, 3rd, Ornstein DK, Paweletz CP, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002; 94: 1576-8.
25. Kozak KR, Amneus MW, Pusey SM, et al. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc Natl Acad Sci USA 2003; 100: 12343-8.
26. Ye B, Cramer DW, Skates SJ, et al. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 2003; 9: 2904-11.
27. Adam BL, Qu Y, DavisJW, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002; 62: 3609-14.
28. Qu Y, Adam BL, Yasui Y, et al. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 2002; 48: 1835-43.
29. Banez LL, Prasanna P, Sun L, et al. Diagnostic potential of serum proteomic patterns in prostate cancer. J Urol 2003; 170: 442-6.
30. Lehrer S, Roboz J, Ding H, et al. Putative protein markers in the sera of men with prostatic neoplasms. BJU Int 2003; 92: 223-5.
31. Hlavaty JJ, Partin AW, Shue MJ, et al. Identification and preliminary clinical evaluation of a 50.8-kDa serum marker for prostate cancer. Urology 2003; 61: 1261-5.
32. Cazares LH, Adam BL, Ward MD, et al. Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. Clin Cancer Res 2002; 8: 2541-52.
33. Wellmann A, Wollscheid V, Lu H, et al. Analysis of microdissected prostate tissue with ProteinChip arrays: a way to new insights into carcinogenesis and to diagnostic tools. Int J Mol Med 2002; 9: 341-7.
34. Koopmann J, Zhang Z, White N, et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 2004; 10: 860-8.
35. Rosty C, Christa L, Kuzdzal S, et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res 2002 62: 1868-75.
36. Vlahou A, Laronga C, Wilson L, et al. A novel approach toward development of a rapid blood test for breast cancer. Clin Breast Cancer 2003; 4: 203-9.
37. Li J, Zhang Z, Rosenzweig J, et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002; 48: 1296-304.
38. Becker S, Cazares LH, Watson P, et al. Surfaced-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-I and sporadic breast cancer. Ann Surg Oncol 2004; 11: 907-14.
39. Pusztai L, Gregory BW, Baggerly KA, et al. Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer 2004; 100: 1814-22.
40. Paweletz CP, Track B, Pennanen M, et al. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis Markers 2001; 17: 301-7.
41. Sauter ER, Shan S, Hewett JE, et al. Proteomic analysis of nipple aspirate fluid using SELDI-TOF-MS. Int J Cancer 2004; 17: 17.
42. Kuerer HM, Coombes KR, Chen JN, et al. Association between ductal fluid proteomic expression profiles and the presence of lymph node metastases in women with breast cancer. Surgery 2004; 136: 1061-9.
43. Zhukov TA, Johanson RA, Cantor AB, et al. Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. Lung Cancer 2003; 40: 267-79.
44. Xiao X, Liu D, Tang Y, et al. Development of proteomic patterns for detecting lung cancer. Dis Markers 2003; 19: 33-9.
45. Rogers MA, Clarke P, Noble J, et al. Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res 2003; 63: 6971-83.
46. Won Y, Song HJ, Kang TW, et al. Pattern analysis of serum proteome distinguishes renal cell carcinoma from other urologic diseases and healthy persons. Proteomics 2003; 3: 2310-6.
47. Soltys SG, Le QT, Shi G, et al. The use of plasma surface-enhanced laser desorption/ionization time-of-flight mass spectrometry proteomic patterns for detection of head and neck squamous cell cancers. Clin Cancer Res 2004; 10: 4806-12.
48. Wadsworth JT, Somers KD, Stack BC Jr, et al. Identification of patients with head and neck cancer using serum protein profiles. Arch Otolaryngol Head Neck Surg 2004; 130: 98-104.
49. Melle C, Ernst G, Schimmel B, et al. Biomarker discovery and identification in laser microdissected head and neck squamous cell carcinoma with ProteinChip(R) technology, two-dimensional gel electrophoresis, tandem mass spectrometry, and immunohistochemistry. Mol Cell Proteomics 2003; 2: 443-52.
50. Melle C, Kaufmann R, Hommann M, et al. Proteomic profiling in microdissected hepatocellular carcinoma tissue using ProteinChip technology. Int J Oncol 2004; 24:885-91.
51. Wilson LL, Tran L, Morton DL, Hoon DS. Detection of differentially expressed proteins in early-stage melanoma patients using SELDI-TOF mass spectrometry. Ann Ny Acad Sci 2004; 1022: 317-22.
52. Vlahou A, Schellhammer PF, Mendrinos S, et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 2001; 158: 1491-502.
53. Krieg RC, Fogt F, Braunschweig T, et al. ProteinChip array analysis of microdissected colorectal carcinoma and associated tumor stroma shows specific protein bands in the 3.4 to 3.6 kDa range. Anticancer Res 2004; 24: 1791-6.
54. Shiwa M, Nishimura X, Wakatabe R, et al. Rapid discovery and identification of a tissue-specific tumor biomarker from 39 human cancer cell lines using the SELDI ProteinChip platform. Biochem Biophys Res Commun 2003; 309: 18-25.
55. Chen YD, Zheng S, Yu JK, Hu X. Artificial neural networks analysis of surface-enhanced laser desorption/ionization mass spectra of serum protein pattern distinguishes colorectal cancer from healthy population, Clin Cancer Res 2004; 10: 8380-5.
56. Wong YF, Cheung TH, Lo KW, et al. Protein profiling of cervical cancer by protein-biochips: proteomic scoring to discriminate cervical cancer from normal cervix. Cancer Lett 2004; 211: 227-34.